Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
Arjun Vasant Balar(NYU Langone Health), Matthew D. Galsky(Icahn School of Medicine at Mount Sinai), Jonathan E. Rosenberg(Memorial Sloan Kettering Cancer Center), Thomas Powles(University College London), Daniel P. Petrylak(Yale University), Joaquim Bellmunt(Harvard University), Yohann Loriot(Institut Gustave Roussy), Andrea Necchi(Fondazione IRCCS Istituto Nazionale dei Tumori), Jean Hoffman‐Censits(Sidney Kimmel Cancer Center), José Luis Perez‐Gracia(Clinica Universidad de Navarra), Nancy A. Dawson(Georgetown University), Michiel S. van der Heijden(The Netherlands Cancer Institute), Robert Dreicer(University of Virginia), Sandy Srinivas(Stanford University), Margitta Retz(Klinikum rechts der Isar), Richard W. Joseph(Mayo Clinic in Florida), Alexandra Drakaki(University of California, Los Angeles), Ulka N. Vaishampayan(The Barbara Ann Karmanos Cancer Institute), Srikala S. Sridhar(Princess Margaret Cancer Centre), David I. Quinn(University of Southern California), Ignacio Durán(Hospital Universitario Virgen del Rocío), David R. Shaffer(New York Oncology Hematology), Bernhard J. Eigl(BC Cancer Agency), Petros Grivas(Cleveland Clinic), Evan Y. Yu(University of Washington), Shi Li, Edward E. Kadel, Zachary Boyd, Richard Bourgon, Priti S. Hegde, Sanjeev Mariathasan, AnnChristine Thåström, Oyewale O. Abidoye, Gregg Fine, Dean F. Bajorin(Memorial Sloan Kettering Cancer Center)
Cited by 2,202Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis